Twin Birth-Studie

Der optimale Geburtsmodus bei Zwillingen
Dr. med. Maria Delius M.P.H. u. PD Dr. med. Uwe Hasbargen Reinhard Henschler
Seiten 6-8

  1. Barrett JFR, Hannah ME, Hutton EK et al.: A Randomized Trial of Planned Cesarean or Vaginal Delivery for Twin Pregnancy. N Engl J Med 2013; 369:1295.
  2. Fell DB, Joseph K: Temporal trends in the frequency of twins and higher-order multiple births in Canada and the United States. BMC Pregnancy Childbirth 2012; 12:103.
  3. Hoffmann E, Oldenburg A, Rode L, Tabor A, Rasmussen S, Skibsted L: Twin births: cesarean section or vaginal delivery? Acta Obstet Gynecol Scand. 2012; 91(4):463-469.
  4. Smith GC, Fleming KM, White IR: Birth order of twins and risk of perinatal death related to delivery in England, Northern Ireland, and Wales, 1994-2003: retrospective cohort study. BMJ 2007; 334 (7593):576.
  5. Rabinovici J, Barkai G, Reichman B, Serr DM, Mashiach S: Randomized management of the second nonvertex twin: vaginal delivery or cesarean section. Am J Obstet Gynecol. 1987; 156(1):52-56.
  6. Arabin B, Kyvernitakis I, Liao A, Zugaib M: Trends in cesarean delivery for twin births in the United States: 1995-2008. Obstet Gynecol. 2012; 119(3):657-658.
  7. Hannah ME, Hannah WJ, Hewson SA, Hodnett ED, Saigal S, Willan AR: Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial. Term Breech Trial Collaborative Group. Lancet. 2000; 356 (9239):1375-1383.
  8. Cheung YB, Yip P, Karlberg J: Mortality of twins and singletons by gestational age: a varying-coefficient approach. Am J Epidemiol. 2000 Dec 15; 152(12):1107-1116.
  9. Armson BA, O'Connell C, Persad V, Joseph KS, Young DC, Baskett TF: Determinants of perinatal mortality and serious neonatal morbidity in the second twin. Obstet Gynecol. 2006; 108:556-564.

CME-Fortbildung: Nonkontrazeptiver Nutzen oraler Kontrazeptiva

Zusatzindikationen und zusätzlicher Nutzen der Pille
Dr. med. Corinna Mann u. Prof. Dr. med. Christian J. Thaler
Seiten 19-24

  1. Liu Z, Doan QV, Blumenthal P, Dubois RW: A systematic review evaluating health-related quality of life, work impairment and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007; 10(3):183-194.
  2. Prentice A: Health care implications of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999; 13(2):181-188.
  3. Davis A, Godwin A, Lippman J et al.: Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000; 96:913.
  4. Larsson G, Milsom I, Lindstedt G, Rybo G: The influence of a low dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992; 46:327–334.
  5. Farquhar C, Brown J: Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2009; CD000154.
  6. Fraser IS, McCarron G: Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Australian & New Zealand Journal of Obstetrics & Gynaecology 1991; 31:66–70.
  7. Shaaban MM, Shabaan MM, Zakherah MS: Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 2011; 83:48.
  8. Andersch B and Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 1982; 144:655–660.
  9. Sundell G, Milsom I und Andersch B: Factors influencing the preva- lence and severity of dysmenorrhea in young women. Br J Obstet Gynaecol 1990:97, 588–594.
  10. Jamieson DJ, Steege JF: The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996; 87:55–58.
  11. Dawood MY: Primary Dysmenorrhea - Advances in pathogenesis and management. Obstetrics Gynaecology 2006; 108:428–441.
  12. Zahradnik HP: Regelschmerzen und Ovulationshemmer – Untersuchungen zum Wirkungsmechanismus. Gyn 2003; 8:2–4.
  13. Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H: Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol. 1995; 9:307-312.
  14. Dawood MY, Khan-Dawood FS: Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2alpha in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea. Am J Obstet Gynecol. 2007; 196:35.e1-5.
  15. Wong CL, Farquhar C, Roberts H, Proctor M: Oral contraceptive pill for primary dysmenorrhoea. Cochrane Analyse; 2009.
  16. Winkler UH, Ferguson H, Mulders JAPA: Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20?g ethinylestradiol. Contraception 2004; 69:469–476.
  17. Dmitrovic R, Kunselman AR, Legro RS: Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol. 2012; 119:1143-1150.
  18. Kurshan N, Neill Epperson C: Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Womens Ment Health. 2006 Jan; 9:1-14.
  19. Winer SA, Rapkin AJ: Premenstrual disorders: prevalence, etiology and impact. J Reprod Med. 2006 Apr; 51:339-347.
  20. Lopez LM, Kaptein AA, Helmerhorst FM: Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev; 2009.
  21. Yonkers KA, Brown C, Pearlstein TB: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106:49.
  22. Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L, Mirkin S, Constantine GD: An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012 May; 85:437-445.
  23. Scharff L, Turk DC, Marcus DA: Triggers of headache episodes and coping responses of headache diagnostic groups. Headache 1995; 35:397.
  24. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part I. Headache 2006; 46:3.
  25. Sulak P, Willis S, Kuehl T: Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 2007; 47:27.
  26. Mac Gregor: Contraception and Headache. Headache 2013; 53: 247-256.
  27. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM and Jorizzo JL: Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997; 89:615–622.
  28. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J und Harrison DD: A randomized, controlled trial of a low-dose contraceptive con- taining 20 mg of ethinyl estradiol and 100 mg of levonorgestrel for acne treatment. Fertil Steril 2001; 76:461–468.
  29. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA: Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev; 2012.
  30. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R: The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69:2–15.
  31. Kelly S, Davies E, Fearns S, McKinnon C, Carter R, Gerlinger C: Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study. Clinical Drug Investigation 2010; 5:325–336.
  32. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N: Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203:38–344.
  33. Carlborg L: Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstetricia et Gynecologica Scandinavica 1986; 134:29–32.
  34. Dieben TO, Vromans L, Theeuwes A, Bennink HJ: The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994; 50:373–382.
  35. Vartiainen M, de Gezelle H, Broekmeulen CJ: Comparison of the effect on acne with a combiphasic desogestrel- containing oral contraceptive and a preparation containing cyproterone acetate. European Journal of Contraception and Reproductive Health Care 2001; 6:46–53.
  36. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster A et al.: Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int. Journal of Fertility and Menopausal Studies 1996; 41:423–429.
  37. Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P et al.: Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Dermato-Venereologica 1984; 64:517–523.
  38. Rosen MP, Breitkopf DM, Nagamani M: A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Amer J of Obstet and Gynecology 2003; 188:1158–1160.
  39. Winkler UH, Ferguson H, Mulders JAPA: Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 ?g ethinylestradiol. Contraception 2004; 69: 469–476.
  40. Thorneycroft H, Gollnick H, Schellschmidt I: Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74:123–130.
  41. Mansour D, Verhoeven C, Sommer W, Weisberg E: Taneepanichskul S, Melis GB, et al.Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17?-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. European Journal of Contraception and Reproductive Health Care. 2011/10/15 2011; Vol. 16, issue 6: 430–443.
  42. Harada T, Momoeda M, Taketani Y et al: Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90:1583.
  43. Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Savelli L, Venturoli S: Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 2010; 94:464-471.
  44. Vercellini P, Trespidi L, Colombo A: A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60:75.
  45. Zupi E, Marconi D, Sbracia M: Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 2004; 82:1303.
  46. Guzick DS, Huang LS, Broadman BA: Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011; 95:1568.
  47. Vercellini P, Frontino G, De Giorgi et al: Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80:560.
  48. Steinkampf MP, Hammond KR, Blackwell RE: Hormonal treatment of functional ovarian cysts: a randomized, prospective study. Fertil Steril. 1990; 54(5):775-777.
  49. Turan C, Zorlu CG, Ugur M, Ozcan T, Kaleli B, Gökmen O: Expectant management of functional ovarian cysts: an alternative to hormonal therapy. Int J Gynaecol Obstet. 1994; 47:257-60.
  50. MacKenna A, Fabres C, Alam V, Morales V: Clinical management of functional ovarian cysts: a prospective and randomized study. Hum Reprod. 2000; 15:2567-2569.
  51. Bayar U, Barut A, Ayo?lu F: Diagnosis and management of simple ovarian cysts. Int J Gynaecol Obstet. 2005; 91:187-188.
  52. Kaufman DW, Shapiro S, Slone D, Rosenberg L, Miettinen OS, Stolley PD: Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 1980; 303:1045–1047.
  53. Hulka BS, Chambless LE, Kaufman DG, Fowler WC Jr, Greenberg BG: Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 1982; 247:475–457.
  54. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I: Use of oral contraceptives and endometrial cancer risk. Cancer Causes Control 1999; 10:277–284.
  55. Voigt LF, Deng Q, Weiss NS: Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control 1994; 5:227–233.
  56. Rosenblatt KA, Thomas DB: Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49:870–874.
  57. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Lancet 2008; 371:303–314.

Mikronährstoffe in verschiedenen Lebensphasen der Frau (Teil 1)

Doppelbelastung: Der Spagat zwischen Esstisch und Büro

Dr. oec. troph. Isabel Behrendt, Dr. rer. nat. Janina Willers, Prof. Dr. med. Peyman Hadji u. Prof. Dr. oec. troph. Andreas Hahn
Seiten 33-37

  1. Max Rubner Institut, Bundesforschungsinstitut für Ernährung und Lebensmittel, Karlsruhe (Hrsg.): Nationale Verzehrsstudie II Ergebnisteil 2: (Zugriff: 26.10.2013).
  2. Wolters M, Hahn A: Nährstoffsupplemente aus Sicht des Konsumenten. Ernährungsumschau. 2001; 48 (4):136-141.
  3. Ströhle A, Hahn A: Nährstoffsupplemente - Möglichkeiten und Grenzen. Teil 1: Von den rechtlichen Rahmenbedingungen zur Ergänzungsfunktion. MMP. 2013; 36 (5):179-190.
  4. Ströhle A, Hahn A. Auf der Suche nach dem evidenzbasierten Gral - Ernährungswissenschaftliche Aussagen im Zeitalter der evidenzbasierten Medizin. Aktuel Ernährungsmed. 2010; 35(6):316-328.
  5. Cramm C, Blossfeld H-P, Drobnic S. Die Auswirkungen der Doppelbelastung von Familie und Beruf auf das Krankheitsrisiko von Frauen. Zeitschrift für Soziologie. 1998; 27, 5, 341-357.
  6. Techniker Krankenkasse (TK): Bleib locker, Deutschland! TK-Studie zur Stresslage der Nation. URL: /tk-stressstudie/611776 (Zugriff: 01.11.2013).
  7. Nestlé Deutschland AG. Nestlé Studie 2011 - So is(s)t Deutschland. Matthaes Verlag, Stuttgart.
  8. Davison KM, Kaplan BJ: Vitamin and mineral intakes in adults with mood disorders: comparisons to nutrition standards and associations with sociodemographic and clinical variables. J Am Coll Nutr. 2011; 30(6): 547-558.
  9. Ecemis GC, Atmaca A: Quality of life is impaired not only in vitamin D deficient but also in vitamin D-insufficient pre-menopausal women. J Endocrinol Invest. 2013; 36(8): 622-627.
  10. Kjærgaard M, Joakimsen R, Jorde R: Low serum 25-hydroxyvitamin D levels are associated with depression in an adult Norwegian population. Psychiatry Res. 2011; 30; 190(2-3): 221-225.
  11. Milaneschi Y, Shardell M, Corsi AM, Vazzana R, Bandinelli S, Guralnik JM, Ferrucci L: Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. J Clin Endocrinol Metab. 2010; 95(7): 3225-3233.
  12. Heseker H, Stahl A: Vitamin B6. Ernährungs-Umschau. 2008; 2:102-107.
  13. Nanri A, Pham NM, Kurotani K, Kume A, Kuwahara K, Sato M, Hayabuchi H, Mizoue T: Serum pyridoxal concentrations and depressive symptoms among Japanese adults: results from a prospective study. Eur J Clin Nutr. 2013; 67(10):1060-1065.
  14. Rosenberg IH, Miller JW: Nutritional factors in physical and cognitive functions of elderly people. Am J Clin Nutr 1992; 55:1237S-1243S.
  15. Pan WH, Chang YP, Yeh WT, Guei YS, Lin BF, Wei IL, Yang FL, Liaw YP, Chen KJ, Chen WJ: Co-occurrence of anemia, marginal vitamin B6, and folate status and depressive symptoms in older adults. J Geriatr Psychiatry Neurol. 2012; 25(3):170-8. doi: 10.1177/0891988712458365.
  16. Malouf R, Grimley Evans J: Vitamin B6 for cognition. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004393. DOI: 10.1002/14651858.CD004393.
  17. Stahl A, Heseker H: Vitamin B12 (Cobalamine). Ernährungs-Umschau. 2007; 10:594-600.
  18. Beydoun MA, Shroff MR, Beydoun HA, Zonderman AB: Serum folate, vitamin B-12, and homocysteine and their association with depressive symptoms among U.S. adults. Psychosom Med. 2010; 72(9):862-873.
  19. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T: Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997; 154 (3):426–428.
  20. Bottiglieri T, Laundy M, Crellin R, Toone BK, Craney MWP, Reynolds EH: Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000; 69:228-232 .
  21. Sen CK, Khanna S, Roy S: Tocotrienol: the natural vitamin E to defend the nervous system? Ann N Y Acad Sci. 2004; 1031:127-142.
  22. Khanna S, Roy S, Slivka A, Craft TK, Chaki S, Rink C, Notestine MA, DeVries AC, Parinandi NL, Sen CK: Neuroprotective properties of the natural vitamin E alpha-tocotrienol. Stroke. 2005; 36(10):2258-2264.
  23. Martin A, Janigian D, Shukitt-Hale B, Prior RL, Joseph JA: Effect of vitamin E intake on levels of vitamins E and C in the central nervous system and peripheral tissues: implications for health recommendations. Brain 1999; 845(1):50-59.
  24. Muller DP: Vitamin E and neurological function. Mol. Nutr. Food Res. 2010; 54:710-718.
  25. Stahl A, Heseker H: Vitamin E. Ernährungs-Umschau 2010; 11:608-615.
  26. Miwa K, Fujita M: Fluctuation of serum vitamin E (alpha-tocopherol) concentrations during exacerbation and remission phases in patients with chronic fatigue syndrome. Heart Vessels. 2010; 25(4):319-23.
  27. Schuchardt JP, Hahn D, Hahn A: Magnesium. DLR. 2008:23-31.
  28. Seeling MS: Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). J Am Coll Nutr. 1994; 13(5): 429-446.
  29. Cernak I, Savic V, Kotur J, Prokic V, Kuljic B, Grbovic D, Veljovic M: Alterations in magnesium and oxidative status during chronic emotional stress. Magnes Res. 2000; 13(1): 29-36.
  30. Galland L: Magnesium, stress and neuropsychiatric disorders. MangnesTrace Elem 2008; 10:287–301.
  31. Nielsen FH, Johnson LK, Zeng H: Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep. Magnes Res. 2010; 23(4):158-168.
  32. Köseoglu E, Talaslioglu A, Gönül AS, Kula M: The effects of magnesium prophylaxis in migraine without aura. Magnes Res. 2008; 21(2):101-108.
  33. Peikert A, Wilimzig C, Köhne-Volland R: Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16 (4):257–263.
  34. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Göbel H, Fischer M: Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study. Cephalalgia. 1996; 16(6):436-440.
  35. Calder PC: Omega-3-Fettsäuren. Schweizer Zeitschr Ernährungmed 2008; 5:23-28.
  36. Willers J, Schuchardt JP, Hahn A: Die Bedeutung langkettiger mehrfach ungesättigter Fettsäuren für die kognitive Entwicklung. SZE. 2012; 2:6-12.
  37. Singer P: Praktische Aspekte bei der Zufuhr von Omega-3-Fettsäuren. Ernährung & Medizin 2010; 15:13-18.
  38. International Society for the Study of Fatty Acids and Lipids (ISSFAL). Adequate Intakes/Recommendation Table: (Zugriff 11.11.2013).
  39. Hausteiner C, Bornschein S, Zilker T, Förstl H, Graßmann J: Über den möglichen Einfluss der Ernährung auf die psychische Gesundheit. Nervenarzt. 2007; 78:696-705.
  40. Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM: Docosahexaenoic acid and post-partum depression - is there a link? Asia Pac J Clin Nutr. 2003;12 Suppl:S37.
  41. Meyer BJ, Grenyer BF, Crowe T, Owen AJ, Grigonis-Deane EM, Howe PR: Improvement of major depression is associated with increased erythrocyte DHA. Lipids. 2013; 48(9):863-8.
  42. Appleton KM, Rogers PJ, Ness AR: Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010; 91(3):757-770.
  43. Kraguljac NV, Montori VM, Pavuluri M, Chai HS, Wilson BS, Unal SS: Efficacy of omega-3 fatty acids in mood disorders - a systematic review and metaanalysis. Psychopharmacol Bull. 2009; 42(3):39-54.
  44. Lin PY, Su KP: A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007; 68(7):1056-1061.
  45. Davison KM, Kaplan BJ: Nutrient intakes are correlated with overall psychiatric functioning in adults with mood disorders. Can J Psychiatry 2012; 57(2):85-92.